Peking University People's Hospital, Beijing, Beijing Municipality, China (Recruiting) - 04 Aug `26MH004 ointment for nonsegmental vitiligo

MH004 ointment for nonsegmental vitiligo

Official title: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Adolescent and Adult Subjects With Non-segmental Vitiligo

Status: Recruiting now

Description:

Minghui Pharmaceutical (Hangzhou) Ltd plans to enroll about 405 participants. The experimental topical medicine is designed to reduce inflammation in vitiligo-affected skin. Researchers hope it will protect melanocytes and improve repigmentation. Possible effects may include redness, itching, burning, acne-like bumps, and infection; its full safety profile is still being studied. People ages 12 to 75 may qualify. The study is recruiting at one listed site in China.

Start date: August 04, 2026

Completion date: October 04, 2028

Organizer: Minghui Pharmaceutical (Hangzhou) Ltd

Contact: CMO/ Senior Vice President of R&D

Tel.: + 86 0571-86963293

Email: jwshi@minghuipharma.com

Link: https://clinicaltrials.gov/study/NCT07682506

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference MH004 ointment for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions